A bispecific antibody against LRP6, blocking its stimulation in the presence of Wnt and R-spondin ligands, has been shown to delay tumor growth in vivo in a patient-derived xenograft model of colorectal cancer [42]. Here, RSPO1 is linked to colorectal cancer.